We are in the age of discovery, seizing a unique moment in time.
WE ARE LIVING THROUGH

A Scientific and Technological Revolution

that is transforming healthcare as we know it - creating opportunities to confront the most pressing challenges facing modern day health systems.

aMoon is here to accelerate this change.
Table of Contents

Chapter One - 6
Investing in the Future of Health

Chapter Two - 15
aMoon at a Glance

Chapter Three - 21
Year in Review

Chapter Four - 24
Impact Thesis

Chapter Five - 39
Investor Additionality

Chapter Six - 50
Our Impact Management Frameworks

Chapter Seven - 58
Our People

Chapter Eight - 63
Disclaimer
Managing Partner Forward

aMoon was founded in 2017 to harness the rapid convergence of healthcare and technology with the mission of Accelerating Cure. With this goal in mind, we work to fund pioneering solutions that tackle healthcare’s most pressing challenges while simultaneously producing exceptional returns for our LPs. At aMoon, we see these goals naturally align, as creating long-lasting impact and sustainable value is deeply connected to our ability to advance technologies that help people live healthier, longer, and better lives.

Our focus on impact allows us to form a common language with our partners and stakeholders, which connects us more deeply to the key innovators in the healthcare value chain. By engaging with ESG principles, we become better investors. Investors in the private and public markets are increasingly looking to invest in companies that embed ESG into their core business practices. As regulators in Europe and the US plan to require investors to be ESG compliant, we aim to not only be prepared, but to remain ahead of the curve.

A large focus of our activities in 2021 revolved around creating the framework to incorporate ESG considerations into our investment activities, in line with industry guidance and the United Nations Sustainable Development Goals. I’m proud to say that we have built an engine that embeds ESG into aMoon’s internal operations, our investment outlook, and our due diligence process.

Impact is at the core of our mission and the cornerstone of everything we do at aMoon. I believe that the work we have done over the course of this past year to enhance our impact management has pushed us further along our mission to advance solutions that will help improve access to care, quality of care, and cost of care to Accelerate Cure.

Thank you,
Dr. Yair Schindel
Managing Partner, aMoon Fund
Our Vision for the Future of HealthTech

Discoveries are being made quicker. Healthcare is no longer a place where we need to wait 20 years to see a scientific discovery make a real impact on peoples’ lives. We are seeing this revolution play out before our eyes, and it is exhilarating.

THE 5 CRUCIAL A’S DRIVING THE HEALTHTECH REVOLUTION:

ACCESSIBILITY
The advent of digital platforms such as telemedicine is creating a tremendous impact on health equity and a more democratized system of care.

AFFORDABILITY
One of the most valuable aspects of digital health is its power to dramatically reduce the cost of care, which in turn dramatically increases patients’ capacity to engage and utilize existing treatments.

ACCURACY
We are witnessing the arrival of digital instruments that help us detect and study disease with levels of precision and personalization that were unimaginable just a few years ago.

ADVANCEMENTS
Empowering physicians and their patients to get ahead of disease by enabling early detection and prevention, which is crucial to improving long term healthcare outcomes.

ACCELERATING CURE
Healthcare innovation no longer requires decades-long research and development processes to impact peoples’ lives. This exciting and transformative revolution is happening right before our eyes.
Harvesting a deep blue ocean of innovation to revolutionize healthcare.

As healthcare costs rise to unsustainable levels and life spans increase, there is an acute need and unprecedented potential for technology to revolutionize healthcare. The convergence of biology and technology has created enormous potential to improve the quality, affordability and access to healthcare. It is time to realize the potential for HealthTech to not only extend life, but to improve our quality of life: to provide proactive, not just reactive care. To prevent, not only to treat.
RNA therapies to activate genes and cure cancer and other diseases

CASE STUDY

MiNA Therapeutics

Activating RNA (RNAa) is an entirely new class of medicines with potential to generate a variety of transformational treatments for patients across a wide range of diseases, from cancer to rare genetic disorders and more.

MiNA Therapeutics has developed a first-in-class RNAa therapy that activates the immune response in the tumor and has demonstrated unprecedented initial results for patients with advanced liver cancer.
MiNA Therapeutics

RNA THERAPIES TO ACTIVATE GENES AND CURE CANCER AND OTHER DISEASES

42k+
PEOPLE DIAGNOSED WITH LIVER CANCER IN THE US PER YEAR

~80%
OF PROTEINS ARE UNDRUGGABLE BY CONVENTIONAL MEDICINES

50K
POTENTIAL GENE TARGETS

$2.4M
RNAa PRODUCT SEQUENCES

UP TO
$1.25B
VALUE OF RECENTLY SIGNED RESEARCH COLLABORATION WITH ELI LILLY

Source(s): MiNA company data, 2022; American Society of Clinical Oncology, 2021
Navigating data in a health system can be challenging, expensive, and time-consuming. Answering simple healthcare related questions can take months or longer due to siloed systems, complex data models, privacy regulations, and limited dedicated resources.

The MDClone ADAMS Platform is a powerful, self-service data analytics environment empowering any user to securely organize and access information, explore ideas, and find insights that power research, drive better patient outcomes, and create impactful healthcare innovation. Within the platform, users can quickly ask questions, refine queries and explore trends and patterns all while protecting patient privacy with groundbreaking synthetic data technology. MDClone’s synthetic data generation is non-reversible, creating artificial data that replicates the statistical characteristics and correlations of original data sets.

MDClone provides the tools – and underlying technology – to integrate healthcare data from disparate sources and provide never-before possible clinical and operational insights for health systems, life science organizations, and healthcare technology companies.

IMPACT PILLARS

PARADIGM SHIFTING BREAKTHROUGHS

Democratizing healthcare big data
**MDClone**

**DEMOCRATIZING HEALTHCARE BIG DATA**

- **50M** Patient datapoints available in MDClone’s Synthetic Data Engine
- **$15M** Annual cost savings at Intermountain Healthcare (MDClone partner)
- **85+** Entrepreneurs utilizing Synthetic Data
- **12** Electronic medical record systems integrated with the MDClone platform
- **350+** Research projects underway using Synthetic Data

*aMoon 2021 Impact Report*

Source(s): MDClone company data, 2022
Preterm birth has both immediate and long-term medical, financial, and emotional implications on mothers, babies, and families as a whole. At present, there is no method available to predict premature birth risk. Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better monitor pregnancies, and proactively address risks of adverse pregnancy outcomes.

Sera Prognostics created a platform to discover, develop and commercialize biomarker tests for major pregnancy-related conditions. Sera’s first commercial product, the PreTRM® Test, is the only broadly validated, commercially available blood-based biomarker test to predict the risk of preterm birth. Additionally, Sera develops tests for several other pregnancy conditions with the aim of significantly improving maternal and neonatal health and dramatically reducing healthcare costs.
Sera Prognostics

FIRST DIAGNOSTIC TEST TO DETECT RISK OF PRE-TERM BIRTH

1M
ANNUAL GLOBAL NEWBORN DEATHS DUE TO PRETERM BIRTH COMPLICATIONS

$25B
ANNUAL U.S. HEALTHCARE COSTS TO MANAGE PREMATURE BIRTH COMPLICATIONS*

$850M
POTENTIAL TO BE SAVED ANNUALLY IN U.S. INDIVIDUAL AND EMPLOYER-SPONSORED HEALTH PLANS*

33%
REDUCTION IN PRE-TERM BIRTHS <32 WEEKS’ GESTATION*

10%
REDUCTION IN NEONATAL INTENSIVE CARE ADMISSIONS*

>1
IN 10 BABIES ARE BORN PREMATURE


*Assuming full uptake of Sera’s test-and-treat strategy: identifying pregnant women at risk and subsequently enabling evidence-based interventions.
Chapter 02

aMoon at a Glance
Purpose-built platform to invest in HealthTech
Venture Funds

**PLATFORM**
- Alpha
- IR & Storytelling
- Finance & Operations
- Legal
- Compliance

**VELOCITY** | 2019 VINTAGE
- Early-stage venture formation/Seed/A
- Closed end

**GROWTH I** | 2018 VINTAGE
- Late-stage B/C/D
- Closed end

**GROWTH II** | 2021 VINTAGE
- Late-stage B/C/D
- Closed end

**EDGE**
- Late-stage crossover*/IPO/public
- Long-only
- Open end**

**AUM$114M**

**AUM$750M**

TARGET $750M

2022 GOAL $100M | TARGET $300M

---

* Investing in Crossover rounds is subject to the creation of a fund structure - in cooperation with the Israeli tax authorities - with respect to the tax treatment of non-Israeli LPs in Israel.
** Initial 18 months lockup
aMoon Portfolio

- Adicet Bio
- ALTRUBIO
- ayaia
- Biolijic Design
- biosplice
- CartiHeal
- CAVOS
- eleos
- GraphiteRx
- IBEX
- KARR
- lin
- MDCLONE
- METAIGHT
- Mina Therapeutics
- MOBIION SYSTEMS, INC.
- nanoGhost
- NECTNTX
- omada
- PrognomIQ
- Satellite
- scipher
- SEER
- Sera Prognostics
- SOPHiA
- STEALTH
- theranica
- VIRACTA
- Zebra Medical Vision
The Breadth and Depth of our Network

- **Limited Partners**
  Our investors include large global banks, well known institutional investors, as well as family offices, foundations, and individuals

- **Portfolio Companies**
  Completed 31 investments in HealthTech companies since 2018

- **aMoon Office**
  We operate out of our office in Ra’anana, Israel

- **aMoon Team Experience**
  Our multi-disciplinary team is composed of scientists, physicians, engineers, entrepreneurs and investors with global experience
aMoon Mindset
OUR VALUES

STRIVE FOR PROFESSIONAL EXCELLENCE
- Pursue our mission, relentlessly
- Strive to always be continuously learning
- Go the extra mile to exceed our goals

MAKE A POSITIVE IMPACT
- Do well by doing good
- Accelerate cure
- Build growth engines

WORK AS A TEAM AND BUILD DEEP, TRUSTED RELATIONSHIPS
- Be approachable, collaborative, and respectful
- Give credit & acknowledge your mistakes
Chapter 03

Year in Review
MiNA Therapeutics announces $1.25 billion partnership with Eli Lilly

Up round - Nectin Therapeutics

New Investment: Scipher Medicine

New Investment: BioSplice Therapeutics

New Investment: Lin Health

Biologic Design announces collaborations with Eli Lilly and Nectar

New Investment: Nectin Therapeutics

MINA Therapeutics announces $1.25 billion partnership with Eli Lilly

Up round - Nectin Therapeutics

SOPHA Genetics IPO (NASDAQ: SOPH)

Sera Prognostics IPO (NASDAQ: SERA)

NEW INVESTMENT: GraphiteRx

Bioventus exercises right to purchase Cartiheal for up to $500 million

Stealth completes financing round at $3.5 billion post-money valuation

NEW INVESTMENT: Cavos BioTech

AMoon 2021 IMPACT REPORT

aMoon Annual LP Meeting

Acquisition of Zebra Medical Vision by Nanox Imaging closed

Up round - MOBILion

Ibex Medical Analytics granted Breakthrough Device Designation by FDA

NEW INVESTMENT: Eleos Mental Systems

aMoon Explorer Program Launched

Viracta goes public via reverse merger (NASDAQ: VIRX)

Up round - Metasight Diagnostics

Up round - Ibex Medical Analytics

NEW INVESTMENT: Metasight Diagnostics

NEW INVESTMENT: Ibex Medical Analytics

NEW INVESTMENT: Kahr Medical

NEW INVESTMENT: Sera Prognostics

NEW INVESTMENT: Cavos BioTech

NEW INVESTMENT: Omada Health

NEW INVESTMENT: Adicet Bio announces positive interim clinical trial results

Velocity’s top-up to $114m

First Starfinder cohort

NEW INVESTMENT: aMoon Growth II Launched

aMoon 22

Year in Review: 2021
New Investments in 2021

$168.8M
Chapter 04

Accelerating Cure, Driving Lasting Impact

IMPACT THESIS
Technology has transformed virtually every aspect of our lives. Now, it’s healthcare’s turn.

aMoon is here to accelerate this transformation.

At aMoon, we partner with exceptional management teams that leverage new, disruptive technologies that make a lasting positive impact and introduce cutting-edge solutions to unmet medical needs.

We invest in companies that share our values and are passionate about fulfilling our vision for the future of healthcare.
How We Think About & Measure Impact

We assess impact throughout the entire investment cycle; from screening to investing to portfolio monitoring. We have defined six impact pillars that derive from our mission to accelerate cure.

SAVE & EXTEND LIVES
Save life or meaningfully extend life: innovations that can cure diseases and save lives through breakthrough treatments.

IMPROVE QUALITY OF LIFE
Improve the quality of life for those with chronic diseases: treatments for some of the most challenging unmet needs.

ACCESS TO HEALTHCARE
Better access to healthcare: we back cutting-edge technologies to democratize healthcare and ensure access to affordable, quality health services for all.

REDUCE COSTS
As healthcare costs rise to unsustainable levels we focus on increasing institutions’ capacity and cutting costs.

PARADIGM SHIFTING BREAKTHROUGHS
Enabling the development of groundbreaking technologies transforming the way we diagnose and treat severe disease.

PREDICTIVE & PERSONALIZED MEDICINE
Promote predictive and personalized medicine, and new ways of delivering healthcare: from reactive to predictive, from treatment to prevention, from generic to personalized.
## aMoon Innovation Index

### Velocity

<table>
<thead>
<tr>
<th>Company</th>
<th>Save &amp; Extend Lives</th>
<th>Improve Quality of Life</th>
<th>Access to Healthcare</th>
<th>Reduce Costs</th>
<th>Paradigm Shifting Breakthroughs</th>
<th>Predictive &amp; Personalized</th>
<th>*Impact Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOS</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>eleos</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>3</td>
</tr>
<tr>
<td>GraphiteRx</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>3</td>
</tr>
<tr>
<td>IBEX</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>3</td>
</tr>
<tr>
<td>lin</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>▲ 3</td>
</tr>
<tr>
<td>META Biotech</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>1</td>
</tr>
<tr>
<td>nanoGhost</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>1</td>
</tr>
<tr>
<td>NECT NTx</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>1</td>
</tr>
<tr>
<td>Satellite</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>1</td>
</tr>
</tbody>
</table>

### Growth

<table>
<thead>
<tr>
<th>Company</th>
<th>Save &amp; Extend Lives</th>
<th>Improve Quality of Life</th>
<th>Access to Healthcare</th>
<th>Reduce Costs</th>
<th>Paradigm Shifting Breakthroughs</th>
<th>Predictive &amp; Personalized</th>
<th>*Impact Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adicet Bio</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>▲ 2</td>
</tr>
<tr>
<td>ALTRUBIO</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>2</td>
</tr>
<tr>
<td>ayala</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>2</td>
</tr>
</tbody>
</table>

*Impact stage 1: Early Development  2: Late Development  3: Early Commercialization  4: Late Commercialization  ▲: The company has moved up an impact stage from 2020
### aMoon Innovation Index

**Growth**

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>SAVE &amp; EXTEND LIVES</th>
<th>IMPROVE QUALITY OF LIFE</th>
<th>ACCESS TO HEALTHCARE</th>
<th>REDUCE COSTS</th>
<th>PARADIGM SHIFTING BREAKTHROUGHS</th>
<th>PREDICTIVE &amp; PERSONALIZED</th>
<th>*IMPACT STAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologic Design</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>biosplice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>CartiHeal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>omada</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>pronomIQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>scipher</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>seer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>MDCLONE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>SEERA PROGNOSTICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>MENA Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>MOBILO Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>▲ 3</td>
</tr>
<tr>
<td>SOPHIA*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>theranica</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Stealth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Viracta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>zebra**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
</tbody>
</table>

**Impact stage**

1. Early Development
2. Late Development
3. Early Commercialization
4. Late Commercialization

*Impact stage
descriptions

- **▲** The company has moved up an impact stage from 2020

**Acquired by Nano-X Imaging Ltd.**

---

**2021 IMPACT REPORT**
Driving Lasting Impact

We invest in cutting edge technologies and exceptional entrepreneurs who are harnessing groundbreaking science and innovation to transform healthcare.
Pushing the Boundaries of Science to Accelerate Cure

aMoon portfolio companies are harnessing the power of proteomics, RNA, blood biomarkers, our immune system and more in order to cure diseases and save lives.

HARNESSING IMMUNE CELLS TO CURE DISEASE
Targeting the immune system by activating it to fight diseases such as cancer or modulating it in order to treat immunological diseases.

PRECISELY TARGETING CANCER CELLS
Developing tailor-made therapies that address specific patient and tumor characteristics.

INNOVATIVELY TARGETING FUNDAMENTAL CELLULAR PROCESSES
Developing tools and therapies by tackling universal molecular processes in the cell (DNA, RNA, protein).

SIMPLE BLOOD TEST TO ANALYZE BIOMARKERS & DETECT DISEASE
Creating tools and technologies which will enable and improve early detection of disease through blood tests as well as better treatment selection.
Despite the unprecedented efficacy of existing immunotherapy agents, most patients either fail to respond or, following encouraging initial response, develop resistance over time. Nectin Therapeutics discovered novel escape mechanisms and is developing targeted therapies leveraging its unique insights into the Nectin pathway to allow the immune system to effectively target and destroy difficult-to-treat cancers.
Nectin Therapeutics

OVERCOMING IMMUNO-ONCOLOGY THERAPY RESISTANCE BY LEVERAGING UNIQUE INSIGHTS INTO THE NECTIN PATHWAY

5 assets under development
NECTIN’S NEXT GENERATION ICI’S AND ADC’S REPRESENT A DEEP PIPELINE WITH BOTH MONO AND COMBINATION POTENTIAL.

MD Anderson partnership
THE CANCER FOCUS FUND, AN ONCOLOGY-FOCUSED FUND IN PARTNERSHIP WITH MD ANDERSON, SELECTED NECTIN FOR ITS 3RD INVESTMENT.

>75%
OF SMALL CELL LUNG CANCER PATIENTS OVER-EXPRESS PVR (NECTIN’S LEAD TARGET)

$127B
PROJECTED GLOBAL IMMUNO-ONCOLOGY MARKET BY 2026

80%
OF CANCER PATIENTS DO NOT RESPOND TO APPROVED IMMUNE ONCOLOGY THERAPIES

Q2 2022
LEAD ASSET ENTERING US CLINICAL TRIAL FOR ADVANCED AND METASTATIC SOLID TUMORS.

Source(s): Nectin company data, 2022
CASE STUDY

Satellite Bio

Liver disease represents a major global burden and unmet therapeutic need. Whole and partial liver transplants are the gold standard solutions for liver disease, but persistent donor organ shortage limits the efficacy of liver transplants.

Satellite Biosciences is an early-stage life sciences company leading the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases. Satellite Bio’s technology is based on two decades of research done in award-winning labs at MIT, Harvard, UPenn, and Boston University.

Lab-grown, implantable satellite organs as living therapeutic solutions for serious diseases.
CASE STUDY

Satellite Bio

LAB-GROWN, IMPLANTABLE SATELLITE ORGANS AS LIVING THERAPEUTIC SOLUTIONS FOR SERIOUS DISEASES.

20 Years
SATELLITE’S LEAD PRODUCT IS BASED ON 20 YEARS OF RESEARCH DONE IN THE LABS OF CO-FOUNDERS DR. SANGEETA BHATIA AND DR. CHRIS CHEN FROM HARVARD & MIT

10+
INDICATIONS THAT COULD BE TREATED WITH SATELLITE BIO’S NOVEL TISSUE THERAPEUTICS

<10%
OF GLOBAL TRANSPLANT NEEDS ARE MET

MARKET SIZE OF CHRONIC LIVER DISEASES

$230B

2M
DEATHS PER YEAR ATTRIBUTABLE TO LIVER DISEASE

500M
LIVER DISEASE PATIENTS WORLDWIDE

Investment Focus

By partnering with outstanding management teams and global centers of innovation, we push ourselves to simultaneously improve access to care, quality of care, and cost of care.

We partner with entrepreneurs developing proactive, preventive tools that facilitate earlier diagnosis and treatment of disease. We invest in companies that offer personalized approaches to treatment – both on the diagnostic and therapeutic fronts by pairing therapies to a person’s biological signature. We are focused on companies that can link better healthcare outcomes with payor economics. We are continuously on the lookout for new healthcare delivery models that facilitate better access to care stemming from the convergence with technology.

*AMoon Growth & Velocity companies
Groundbreaking Research

We believe that breakthrough scientific research drives the most transformative HealthTech innovations. We see our role as co-explorers, partnering with outstanding scientists to redefine the way diseases are studied, diagnosed and treated.

SPONSORED RESEARCH

We jump to the head of the line, sponsoring breakthrough research conducted at leading global academic institutions, in collaboration with major pharma, biotech, medtech and digital multi-nationals.

VENTURE FORMATION

Leveraging our company-building skill set, expertise and vast network to co-found new pioneering companies.
The Explorer Program

Highly-disruptive, high-impact proposals for sponsored translational breakthrough academic research in three areas we believe are exciting and on the verge of a major transformation

AREAS OF FOCUS

DIGITAL THERAPEUTICS

NOVEL THERAPEUTIC APPROACHES IN FIBROTIC DISEASES

DISEASES DETECTION & TREATMENT VIA SYNTHETIC BIOLOGY
StarFinder
Digital Innovation Lab

Unique "Build to Buy" Strategic Collaboration Program
Exclusive innovation program for AI-based diagnostics ventures to fast-track 'Proof of Concept' (POC) projects based on validated market needs, joint pre-seed investment with an option to invest post POC and access to data & unique expertise.

THEMES

DYNAMIC CANCER TREATMENT
Next generation diagnostic testing

CHRONIC LIVER DISEASES
Diagnosis, prognosis and prediction

DIGITAL & COMPUTATIONAL PATHOLOGY

AI-BASED
Non/minimal invasive respiratory tract sampling
Chapter 05

Unlocking Value, Amplifying Impact

INVESTOR ADDITIONALITY
Trust isn’t just what aMoon means in Hebrew. It’s what we stand for.

We build partnerships with outstanding entrepreneurs and scientists who are transforming the way we diagnose, treat and cure.
aMoon Value Add

As a global fund headquartered in Israel, we connect our portfolio companies to global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality.

We tap aMoon’s global network to equip entrepreneurs with the expertise, connections, resources, and support they need to accelerate their path to value creation so they can build world leading companies.

Business Development & Strategy
Facilitate introductions to potential customers, collaborators, advisors, and value creation opportunities.

Strategic Communications
Raise company profiles by sharpening branding, media, and storytelling strategy.

Building Syndicates & Financing Readiness
Tailored access to top private and public co-investors & Wall Street leaders to broaden investor base and expand network.

Talent
Leverage our global talent network to identify, engage, and match C-suite & board talent to fill organizational gaps.
Our Bridges program connects aMoon portfolio companies with key ecosystem players in the healthcare field: building “bridges” between Israel and other global HealthTech hubs. Through these relationships, entrepreneurs are able to sharpen their understanding of market needs, refine product market-fit, and execute operational plans with greater impact and speed.

We help our companies build partnerships with top private and public co-investors, Wall Street leaders, research institutions and payers & provider networks, as well as the largest Biopharma, MedTech and Tech corporations in the world.
## Investor Additionality by the Numbers

<table>
<thead>
<tr>
<th>Category</th>
<th>Supported</th>
<th>Conversion Rate to:</th>
<th>Details</th>
</tr>
</thead>
</table>
| **CAPITAL**   | 23/31     | 65%                 | - Follow-on investments  
- Successful introductions to bankers  
- Support ahead of IPO  
- Support in M&A process |
| **PAYORS & PROVIDERS** | 8/31      | 50%                 | - Advanced discussion on pilots with provider networks  
- Payor offering TS  
- Potential partnerships |
| **STRATEGICS** | 20/31     | 20%                 | - Strategic work on defining value proposition  
- Signed collaboration agreements  
- Intras & Support around M&A |
| **SCIENCE**   | 14/31     | 57%                 | - Connections to first customers  
- Connections to clinical sites  
- Assembling scientific & clinical advisory boards  
- Access to bio-samples |
| **TALENT**    | 29/31     | 94%                 | - Executive board and senior management placements  
- Referrals for industry experts and top advisors  
- Access to exclusive talent networks |
| **STORYTELLING** | 17/31     | 59%                 | - Publications in top tier news outlets  
- PR support for financing rounds, IPOs, and rebranding initiatives |

- **CAPITAL**: 23 out of 31 supported, 65% conversion rate
- **PAYORS & PROVIDERS**: 8 out of 31 supported, 50% conversion rate
- **STRATEGICS**: 20 out of 31 supported, 20% conversion rate
- **SCIENCE**: 14 out of 31 supported, 57% conversion rate
- **TALENT**: 29 out of 31 supported, 94% conversion rate
- **STORYTELLING**: 17 out of 31 supported, 59% conversion rate
Our Investment Impact

$2.5 billion

Was raised by our portfolio companies in the public and private rounds after and during our initial investment.
What Our Portfolio Leadership Says

One of the great aspects of our relationship with aMoon has been the depth and breadth of connections we’ve been able to make. aMoon helped us to locate an incredible clinical advisor who has been able to pull us right to the center of the transformation happening in pain science.

Abigail Hirsch, PhD
Lin Health Co-Founder & CPO

During diligence, I was asked to present our system to a new hospital in Canada. It felt like a waste of time. But I remember Yair telling me, ‘Don’t look at it as a test, look at it as an opportunity to open doors’. And here we are today, we’ve signed a contract with this hospital.

Ziv Ofek
MDClone CEO & Founder

The relationship I built with Tomer (aMoon General Partner) is quite profound and very honest. The first time we met in person, it felt like we’d known each other for ten years.

Jurgi Camblong
SOPHiA CEO & Co-founder

It’s been very valuable to get the perspective of a team that reviews company pitches regularly. The experience was productive and insightful, and we were delighted to have the timely and focused support.

Fabian Tenenbaum
Nectin Therapeutics CEO

LEVERAGING THE POWER OF OUR NETWORK TO FOCUS OUR EFFORTS

ALIGNING WITH THE CEO TO BUILD TRUST-BASED RELATIONSHIPS AND VALUE-BASED AGENDA

ADDING VALUE THROUGH DILIGENCE

USING STRATEGIC COMMUNICATIONS TO STRENGTHEN MESSAGING AND BRAND
CASE STUDY

Pharmacy buyers are currently using outdated and unsynchronized technology to procure pharmaceuticals outside of the three primary full-line wholesalers. This process makes it difficult for buyers to manage direct spending and for suppliers to reach the pharmacy buyers.

GraphiteRx’s platform provides pharmacies with a one-stop shop to order the medications and supplies they need from outside their full-line wholesaler and helps suppliers sell directly to health systems, pharmacies, and clinics. GraphiteRx is a modern pharmacy marketplace that is transforming healthcare by reimagining how pharmacies and suppliers do business.

Modern marketplace platform streamlining pharmacy procurement & distribution

IMPACT PILLARS

ACCESS OF HEALTHCARE
REDUCE COSTS
**CASE STUDY**

GraphiteRX

MODERN MARKETPLACE PLATFORM STREAMLINING
PHARMACY PROCUREMENT & DISTRIBUTION

$40B IN PHARMACEUTICAL SPENDING OUTSIDE FULL-LINE WHOLESALERS

6K TOTAL NUMBER OF HOSPITALS IN THE U.S.

300+ ACTIVE SUPPLIERS ON THE PLATFORM

1.5K PHARMA SUPPLIERS IN THE U.S.

Source(s): GraphiteRx company data, 2022
The behavioral healthcare industry is extremely overburdened. With pen and paper as the primary tool for keeping patient notes, which are used as the base for diagnoses and recommendations, a more efficient tool is needed to provide actionable insights that enable clinicians to make data-informed decisions and reduce administrative burden.

Eleos Health developed an AI-backed platform that consolidates the entire behavioral care workflow - from documentation to progress notes to compliance administration – all while providing deep clinical insights through session intelligence. Eleos' platform frees clinicians from the time-consuming operational burdens and enables them to make data-driven decisions and provide better care.

**Powering the future of behavioral health**
INCREASE IN THE NUMBER OF AMERICAN ADULTS WHO REPORT STRUGGLING WITH BEHAVIORAL HEALTH ISSUES FOLLOWING THE COVID-19 PANDEMIC

THE MENTAL HEALTH SERVICES ADMINISTRATION ESTIMATES THAT THERE WILL BE A COMBINED SHORTAGE OF 133,000 MENTAL HEALTH COUNSELORS, SOCIAL WORKERS, AND PSYCHOLOGISTS BY 2025

MENTAL HEALTH CLINICIANS SPEND 20% OF THEIR TIME ON ADMINISTRATIVE TASKS

US SPENDING ON MENTAL HEALTH MARKET SERVICES REACHED 225 BILLION IN 2019, ACCOUNTING FOR NEARLY 5.5% OF ALL HEALTH SPENDING

Source(s): Eleos company data, 2022

CASE STUDY
Eleos health
POWERING THE FUTURE OF BEHAVIORAL HEALTH
Chapter 06
Our Impact
Management Frameworks
Our Approach to Sustainable Investing

We define impact as the “what”; the areas in which we’re changing, disrupting and making a true difference.

For us, ESG is a roadmap for the “how”; the processes and systems we have in place and how we conduct our business.

ESG and Impact go hand in hand: we envision our work in ESG and Impact running in parallel, complementary to one another. Our impact management strategy focuses on the direct impact we seek to achieve through the products and services we bring to market. The integration of ESG factors into our investment engine and operations, will enable us as investors to mitigate risks and identify value creation opportunities.
aMoon is committed to supporting a shift away from high cost, reactive care delivery towards predictive and preventative care that stratifies, flags, and performs proactive outreach to high-risk populations.

**GOOD HEALTH AND WELL-BEING**

Target 3.1 Reduce maternal mortality
Target 3.2 End all preventable deaths under 5 years of age
Target 3.4 Reduce mortality from non-communicable diseases and promote mental health
Target 3.5 Support research, development, and universal access to affordable vaccines and medicines

**DECENT WORK AND ECONOMIC GROWTH**

As the health-tech industry continues to grow, burgeoning technologies are poised to create economic growth engines for nations around the globe, generate high-paying jobs, and leverage this momentum to improve healthcare systems’ efficiency and reduce healthcare costs.

Target 8.1 Sustainable economic growth
Target 8.2 Diversify, innovate and upgrade for economic productivity
Target 8.3 Promote policies to support job creation and growing enterprises

**INDUSTRY INNOVATION AND INFRASTRUCTURE**

Healthcare’s digital convergence will continue to transform the entire life sciences eco-system, offering enhanced capabilities to identify drug targets and conduct drug discovery and development more effectively.

Target 9.5 Enhance research and upgrade industrial technologies
Impact is part of our DNA, it manifests across everything we do

aMOON IS COMMITTED TO THE SDG IMPACT STANDARDS FOR PRIVATE EQUITY FUNDS:

- Contributing positively to sustainable development and achieving the SDGs
- Responsible business practices
- Effective impact management and decision making

STRATEGY

As part of our mission to accelerate cure, positively contributing to sustainable development and achievement the SDGs is inherently at the heart of our purpose and strategy.

MANAGEMENT APPROACH

Integrating impact management into our operations and management approach.

TRANSPARENCY

Disclosing how we contribute to achieving the SDGs through our purpose, strategy, management approach, governance and decision making, and report on our performance.

GOVERNANCE

Our commitment to contributing positively to sustainable development through governance practices and our leadership team.

Source(s): UNDP, 2022
Impact Community

As of 2022 aMoon is a signatory of the UN PRI, joining the leading international network of institutional investors committed to including environmental, social and governance factors in their investment decision making. The decision to join the PRI follows a yearlong review process to strengthen our approach to sustainable investing.

aMoon engaged Social Finance Israel, a leading ESG consulting firm in Israel, to build an ESG framework for evaluating HealthTech startups in accordance with the IMP 5 Dimensions Impact Assessment.

aMoon is a member of The Global Tech Alliance (GITA), a global network of impact-tech practitioners, from investors to organizations, working to address UN Sustainable Development Goals through tech innovation.
Sustainable Investing Journey

- Engaged with Social Finance Israel to build frameworks for ESG integration & impact measurement
- ESG questionnaire for potential investments
- Became UN PRI signatory
- Member of The Global Tech Alliance (GITA)
- Member of VentureESG

- aMoon's inaugural Impact Report published
- Incorporated ESG factors into our investment process

2021 2022
Integrating Impact & ESG into our Investment Lifecycle

**DEAL SCREENING**
Evaluating how the company’s impact vision aligns with our core impact pillars and contribute to our impact thesis.

**INVESTMENT**
Asking the company to complete an ESG footprint questionnaire prior to approving an investment.

Discussing potential impact as part of our investment committee’s decision-making process.

**DUE DILIGENCE**
Assessing the company’s potential substantial societal impact on longevity and quality of life, scientific progression and better healthcare delivery, alongside substantial value for stakeholders.

Thinking about our investor additionality as we look for more ways to add value to companies already in the due diligence process.

**PORTFOLIO MANAGEMENT**
Measuring our portfolio progress towards our core impact pillars on an annual basis.
aMoon Governance

ADVISORY COMMITTEE
Each aMoon fund maintains an advisory committee composed of representatives of investors in such fund. Its primary responsibility is to advise the General Partner regarding certain activities that may represent conflicts of interest between the General Partner and the Limited Partners, and consent of the Advisory Committee is required in order for a fund to take certain actions listed in such fund’s limited partnership agreement.

GENERAL PARTNER
Each aMoon fund has a distinct general partner that is responsible for the fund’s decisions. The General Partner takes decisions with respect to investment and divestment of investments after receiving the recommendation of the Investment Committee.

INVESTMENT COMMITTEE
Each aMoon fund has an investment committee, which provides its recommendations regarding investment in, and divestments from, portfolio companies. Members of the Investment Committees are appointed by the applicable General Partner, and typically consist of, among others, partners in such fund.

COMPLIANCE PRINCIPLES
At aMoon we believe that a strong ethical framework is inextricably linked to long-term business success. We are therefore committed to conducting our investment management business in accordance with the highest legal and ethical standards in furtherance of our clients’ interests and in a manner that is consistent with all applicable laws, rules and regulations.

In order to help aMoon maintain the high level of trust and confidence placed in us by our clients, we have instituted a number of policies governing investment and management activities across the company. These policies, along with the aMoon’s Code of Ethics, are intended to:

- Ensure compliance risks are identified, prioritized and managed in a timely and appropriate fashion;
- Establish an environment of accountability that promotes compliance with applicable laws, regulations and internal policies and procedures at all levels across the company;
- Offer a medium for confidential reporting of potential non-compliant or unethical behavior

CONFLICTS OF INTEREST
We recognize the position of trust and confidence that our clients have placed in us, and are driven by the fiduciary duty to place client interests before our own. This fiduciary duty includes an obligation to avoid both actual conflicts of interest and the appearance of any conflicts of interest. To this end, aMoon has adopted a range of policies that seek to reduce and address conflicts of interest. Certain conflicts of interest are addressed by the Advisory Committee, while other conflicts are reduced by strict rules restricting personal investments by aMoon employees in the health-tech sphere. Every employee is made aware of aMoon’s policies both in trainings and by exposure to our compliance manual.
Chapter 07

Our People
We are a team of scientists, physicians, entrepreneurs and investors with global experience who have dedicated our lives to science, medicine, technology, and progress.
aMoon Team

Deep expertise, global experience & trusted relationships.

59% Female

41% Male

WORK EXPERIENCE
(prior to joining aMoon)

<table>
<thead>
<tr>
<th>Field</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finance</td>
<td>14</td>
</tr>
<tr>
<td>BioTech</td>
<td>9</td>
</tr>
<tr>
<td>Government</td>
<td>6</td>
</tr>
<tr>
<td>Medicine</td>
<td>4</td>
</tr>
</tbody>
</table>

EDUCATION

<table>
<thead>
<tr>
<th>Degree</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBAs</td>
<td>12</td>
</tr>
<tr>
<td>PhDs</td>
<td>6</td>
</tr>
<tr>
<td>MDs</td>
<td>4</td>
</tr>
</tbody>
</table>

73% HAVE A GRADUATE DEGREE

61% HAVE LIVED, WORKED, OR STUDIED IN 2+ COUNTRIES

GENDER

59%

41%

WORLDWIDE

LANGUAGES

- Hebrew
- Italian
- French
- German
- Spanish
- Arabic
- Portuguese
- Japanese
- Mandarin
- Russian
Disclaimer

This presentation (including all information contained herein) is being delivered to parties for the purposes of learning about aMoon’s impact. It is provided on a confidential basis to allow readers to learn more about aMoon (the “Fund”).

This presentation is being provided to you for the sole purpose of affording you with background information about the Fund’s business. Neither the presentation nor anything contained herein forms the basis of any contract or commitment. This presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Fund. This presentation does not purport to summarize all of the conditions, risks, and other attributes of an investment in the Fund and is qualified in its entirety by the information to be made available by the Fund to persons meeting certain investment criteria and not to the public in general.

It is hereby clarified that the offering of interests in the Fund is a private offering and does not constitute and is not intended to constitute an “offer to the public” as defined in the Israeli Securities Law 5729-1968 (the “Israeli Securities Law”), and the interests have not been registered nor is there an intention to register them, under the Israeli Securities Law, or under the laws of any other jurisdiction. Investors in the interests will not be able to rely on such securities law in many matters related to or deriving from their investment in the Fund. The interests will be offered and sold under exemptions provided by the Israeli Securities Law in connection with the foregoing, therefore the offering and sale of securities in the Fund to investors that do not fall under the categories of Section 15a(b) of the Israeli Securities Law will be limited to 35 investors in any 12-month period. Neither the Israeli Securities Authority nor the regulatory authority of any other country, state or jurisdiction has approved or will approve this presentation or the interests referred to herein. Any representation to the contrary is unlawful.

This presentation (including all information contained herein) is provided on a confidential, personal and private basis for use only by the recipient as a wholesale client under the Corporations Act 2001 (Cth) and should not be forwarded to others. The information contained in this document is intended as financial product advice and it does not take into account any person’s investment objectives, financial circumstances or specific needs. This document is neither an offer to sell nor a solicitation of any offer to acquire interests or any other investment and should not be used as the basis for making an investment in the aMoon Growth Fund II L.P. aMoon and Polar Advisory and their directors, officers, employees, agents or associates do not guarantee repayment of capital, the performance of any fund or any service. Past performance is not a reliable indicator of future performance.